Evotec SE (NASDAQ:EVO - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 118,691 shares were traded during mid-day trading, a decline of 12% from the previous session's volume of 134,233 shares.The stock last traded at $4.04 and had previously closed at $4.13.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on EVO shares. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $5.93.
Get Our Latest Stock Analysis on Evotec
Evotec Stock Down 1.2%
The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The firm's fifty day moving average is $3.99 and its two-hundred day moving average is $4.09.
Hedge Funds Weigh In On Evotec
Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in Evotec in the 4th quarter worth approximately $27,000. DCF Advisers LLC grew its stake in Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after acquiring an additional 12,816 shares in the last quarter. CSS LLC IL purchased a new position in Evotec during the fourth quarter valued at $50,000. Lighthouse Investment Partners LLC bought a new stake in Evotec in the 4th quarter valued at $166,000. Finally, Bank of America Corp DE lifted its stake in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. Institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
